Home > Quotes > RARE
RARE

Ultragenyx Pharmaceutical Inc. Common Stock Quote & Summary Data

$69.46
*  
1.84
2.72%
Get RARE Alerts
*Delayed - data as of May 2, 2016  -  Find a broker to begin trading RARE now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Ultragenyx Pharmaceutical Inc. Common Stock Intraday Chart




Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 69.58 $ 137.05
Low $ 65.54 $ 49

The current last sale of $69.46 is 41.76% Higher thanthe 52 week low.

P/E Ratio

ETFs with RARE as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.48% Vanguard Russell 2000 Growth ETF (VTWG) -8.40 (-7.95%)
0.24% Vanguard Russell 2000 ETF (VTWO) -4.32 (-4.58%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. We target diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no currently approved therapies. Since our inception in 2010, we have in-licensed potential treatments for multiple rare genetic disorders. Our strategy, which is predicated upon time- and cost-efficient drug development, allows us to pursue multiple programs in parallel with the goal of delivering safe and effective therapies to patients with the utmost urgency. Our current product candidate pipeline has been either in-licensed from academic institutions or derived from partnerships with other pharmaceutical companies.  ... More ...  

Risk Grade

Where does RARE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?